The historical rank and industry rank for Cyfuse Biomedical KK's FCF Margin % or its related term are showing as below:
TSE:4892'
s FCF Margin % Range Over the Past 10 Years
Min: -1728.78 Med: -233.07 Max: 22.81
Current: -1728.78
During the past 6 years, the highest FCF Margin % of Cyfuse Biomedical KK was 22.81%. The lowest was -1728.78%. And the median was -233.07%.
TSE:4892's FCF Margin % is ranked worse than 97.29% of 958
companies
in the Drug Manufacturers industry
Industry Median: 2.445
vs TSE:4892: -1728.78
Cyfuse Biomedical KK FCF Margin % Related Terms
Cyfuse Biomedical KK FCF Margin % Historical Data
* Premium members only.
The historical data trend for Cyfuse Biomedical KK's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Cyfuse Biomedical KK's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cyfuse Biomedical KK FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cyfuse Biomedical KK's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Cyfuse Biomedical KK's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cyfuse Biomedical KK (TSE:4892) has a FCF Margin % of 0.00% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Cyfuse Biomedical KK and its competitors. According to the industry distribution chart, Cyfuse Biomedical KK ranks #932 out of 958 companies in the Drug Manufacturers industry, placing it in the top 97.3%.
Is Cyfuse Biomedical KK's FCF Margin % too high?
Cyfuse Biomedical KK's current FCF Margin % is 0.00%. Based on the distribution chart, Cyfuse Biomedical KK ranks #932 out of 958 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Cyfuse Biomedical KK has a GF Score™ of 54/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cyfuse Biomedical KK's FCF Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Cyfuse Biomedical KK ranks #932 out of 958 companies for FCF Margin %. This places Cyfuse Biomedical KK in the lower half of its industry. The industry median FCF Margin % is 2.45. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.45, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Cyfuse Biomedical KK and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cyfuse Biomedical KK's current FCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cyfuse Biomedical KK stock overvalued right now?
Based on GuruFocus' analysis, Cyfuse Biomedical KK (TSE:4892) is currently considered Possible Value Trap. The stock's GF Value™ is 円1,962.33, compared to a current price of 円520.00 — trading 73.5% below its estimated fair value. The current FCF Margin % is 0.00%. Cyfuse Biomedical KK's overall GF Score™ is 54/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Cyfuse Biomedical KK (TSE:4892), the current FCF Margin % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cyfuse Biomedical KK (TSE:4892) Overvalued in 2026?
Based on GuruFocus' analysis, Cyfuse Biomedical KK stock appears to be undervalued.
The current stock price of 円520.00 is trading 73.5% below its estimated GF Value™ of 円1,962.33.
GuruFocus considers Cyfuse Biomedical KK to be Possible Value Trap.
Key valuation signals for TSE:4892:
FCF Margin %: 0.00%
GF Value™: 円1,962.33 vs. price of 円520.00 (73.5% below fair value)
No single metric tells the full story. See the TSE:4892 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cyfuse Biomedical KK is engaged in the development, manufacturing, and sales of regenerative medicine-related products. The company focuses on delivering three-dimensional tissues and organs created solely from cells as new 3D cell products to medical fields, including regenerative medicine and drug discovery, through the practical application of three-dimensional cell stacking technology. It is engaged in multifaceted development in the following areas: regenerative medicine, drug discovery support, and the device domain, including the development and sales of 3D cell stacking system equipment, such as bio 3D printers equipped with the company's platform technology.
54GF Score
Get the complete analysis for TSE:4892
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4892 has been successfully added to your 
